Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

PRME


Fundamental

Company: Prime Medicine Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: Small
Index: RUT
P/E: -
EPS (ttm): -1.25
Insider Own: 47.66%
Shs Outstand: 180.62M
Perf Week: -6.63%
Market Cap: 585.20M
Forward P/E: -
EPS next Y: -0.91
Insider Trans: 0.00%
Shs Float: 94.54M
Perf Month: -5.54%
Enterprise Value: 564.21M
PEG: -
EPS next Q: -0.26
Inst Own: 41.49%
Short Float: 31.98%
Perf Quarter: -9.75%
Income: -198.37M
P/S: 145.21
EPS this Y: 26.17%
Inst Trans: 4.42%
Short Ratio: 12.71
Perf Half Y: -22.49%
Sales: 4.03M
P/B: 7.63
EPS next Y Percentage: 9.06%
ROA: -63.69%
Short Interest: 30.24M
Perf YTD: -6.63%
Book/sh: 0.42
P/C: 4.32
EPS next 5Y: 15.53%
ROE: -216.07%
52W High: 6.94 -53.31%
Perf Year: 149.23%
Cash/sh: 0.75
P/FCF: -
EPS past 3/5Y: 2.55% -91.28%
ROIC: -108.60%
52W Low: 1.11 191.89%
Perf 3Y: -74.18%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -2.32%
Gross Margin: -85.35%
Volatility W: 10.74%
Volatility M: 7.10%
Perf 5Y: -
Dividend TTM: -
EV/Sales: 140.00
EPS Y/Y TTM: 24.20%
Oper. Margin: -5121.76%
ATR (14): 0.27
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 3.80
Sales Y/Y TTM: 4.89%
Profit Margin: -4917.55%
RSI (14): 39.47
Recom: 1.67
Dividend Gr. 3/5Y: - -
Current Ratio: 3.80
EPS Q/Q: 30.04%
SMA20: -9.81%
Beta: 2.34
Target Price: 7.16
Payout: -
Debt/Eq: 1.49
Sales Q/Q: -41.13%
SMA50: -11.12%
Rel Volume: 1.34
Prev Close: 3.21
Employees: 146
LT Debt/Eq: 1.38
Earnings: May 07 BMO
SMA200: -19.67%
Avg Volume: 2.38M
Price: 3.24
IPO: Oct 20, 2022
Option/Short: Yes / Yes
EPS/Sales Surpr.: -11.60% -63.24%
Trades:
Volume: 3,191,538
Change: 0.93%

Technical:


Latest News:

Citigroup Upgrades Prime Medicine (PRME) - Nasdaq very bullish
PRME

Summary: Citigroup upgraded their outlook for Prime Medicine from Neutral to Buy with an analyst price forecast suggesting 114.11% upside. Various funds and institutions have reported positions in Prime Medicine, totaling 70,064K shares, with a bullish outlook indicated by the put/call ratio of 0.12.

Full article
2024-05-17T22:16:55Z